Full Press Release Details
Pharmaceuticals, Inc.
Pharmaceuticals Appoints Chief Medical Officer and Chief Operating
Calif., April 24 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC
specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically administered medications, today
announced the appointment of Dr. Paul Finnegan to the position of Chief Medical
Officer and Chief Operating Officer. In his new role, Dr. Finnegan will oversee
the Phase 3 clinical program for Transdel's lead product, Ketotransdel(TM),
novel topical cream based non-steroidal anti-inflammatory drug ("NSAID") for
treatment of acute pain. In addition, Dr. Finnegan will manage the development
and expansion of Transdel's clinical pipeline, leveraging the Company's
proprietary Transdel(TM) technology to develop enhanced generic and novel
products in a broad range of indications and therapeutic areas.
Finnegan brings to the Company over a decade of experience in the development
and commercialization of multiple drugs through leadership roles in both public
and private biotechnology/pharmaceutical companies. His specific pain and
anti-inflammatory therapeutic experience includes Celebrex (celecoxib), Bextra
(valdecoxib), Dynastat (paracoxib), and Arthrotec (diclofenac sodium /
misoprostol) while at Pharmacia/G.D. Searle & Co. Dr. Finnegan joins the
Company from Cecoura Therapeutics, Inc., a privately held biotechnology firm,
where he served as President and Chief Executive Officer from October 2007
Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals,
commented, "We are pleased to welcome Dr. Finnegan to our senior management
team. His extensive biotechnology and pharmaceutical industry experience,
particularly his focus on the areas of pain and inflammation, is directly
relevant to our ongoing clinical development programs. He will not only add
great value to the Phase 3 clinical program for Ketotransdel but also brings
excellent commercial background, which will be an asset as we advance
Ketotransdel to commercialization. Lastly, Dr. Finnegan's knowledge base and
capabilities will be integral to supporting our goal of expanding our pipeline
with innovative topically based products."
Cecoura, Dr. Finnegan was involved in clinical and drug development, where
led and completed an IND submission and was involved in licensing activities.
Dr. Finnegan held various positions at Alexion Pharmaceuticals, Inc. from April
2001 through September 2007. Specifically, from 2006 to 2007, he served as
President, Global Strategic Marketing and Development and as a member of the
Management Committee. In this role, he was directly responsible for building
Alexion's subsidiaries in country markets outside of the U.S. and Europe. From
2002 to 2006, Dr. Finnegan served as Alexion's Vice President of Commercial
Operations and Development. During this period, Dr. Finnegan was one of the
founders of the Soliris(TM) (eculizumab) PNH clinical development and
commercialization programs (US
EU approvals and launches in 2007), intimately involved in three cardiovascular
Phase III clinical registration trials (PRIMO-CABG1, PRIMO-CABG2, APEX-AMI),
member of the Alexion-Procter
and Gamble Pharmaceuticals Alliance Senior Management Team, and played an
instrumental role in building Alexion's European presence. He joined Alexion
Executive Director of Commercial Operations.
to 2000, Dr. Finnegan was Senior Director, Global Medical Marketing at Pharmacia
Corporation, formerly G.D. Searle. While at Pharmacia/G.D. Searle, Dr. Finnegan
served as the medical affairs lead for all therapeutic areas and products
(pain/anti-inflammatory, cardiovascular, women's health and oncology franchises)
for businesses in Japan, Asia-Pacific, Latin America and Canada, and played
key role for the launch of the blockbuster Celebrex / Celebra , the first COX-2
inhibitor indicated for pain, osteoarthritis, and rheumatoid arthritis, in
to 1997, Dr. Finnegan was Director and Partner of Toronto East Radiology
Associates, LLC, and was the co-leader of Vascular and Interventional Radiology
at Toronto East General & Orthopedic Hospital, an affiliated teaching
hospital of the University of Toronto. Dr. Finnegan earned his MBA with Honors,
in Finance and Strategy, from the University of Chicago, Graduate School of
Business. He also holds the degrees of MD, CM from McGill University, Faculty
Medicine, in Montreal and is a Fellow of the Royal College of Physicians, Canada
Transdel Pharmaceuticals, Inc.
Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP
specialty pharmaceutical company pursuing the development and commercialization
of non-invasive topically delivered medications. The Company's lead topical
drug, Ketotransdel, utilizes the Company's innovative patented Transdel(TM)
cream formulation technology to facilitate the passage of ketoprofen, an NSAID,
through the skin barrier to reach targeted underlying tissue where the drug
exert its prolonged localized anti- inflammatory and analgesic effect. The
Company is also investigating other drug candidates and treatments for
transdermal delivery using the patented Transdel platform technology for
products in pain management and other therapeutic areas. For more information,
please visit http://www.transdelpharma.com.
made in this release that are not historical in nature constitute
forward-looking statements within the meaning of the Safe Harbor Provisions
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "expects," "plans,"
"will," "may," "anticipates," "believes," "should," "intends," "estimates,"
other words of similar meaning. These
statements are subject to risks and uncertainties that cannot be predicted
quantified and consequently, actual results may differ materially from those
expressed or implied by such forwardlooking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties associated
with the uncertainty of future financial results, additional financing
requirements, development of new products, government approval processes, the
impact of competitive products or pricing, and technological changes. More
detailed information about the company and the risk factors that may affect
realization of forward-looking statements is set forth in the company's filings
with the Securities and Exchange Commission, including the company's Annual
Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents
be read free of charge on the SEC's web site at http://www.sec.gov.
forward-looking statements included in this release are made as of the date
release, and the company assumes no obligation to update any such
forward-looking statements.